Tag

OxThera AB

Phase 3 ePHex Study: OxThera Reports Results

Sid Martin Biotech alum OxThera AB, a biopharma company dedicated to improving the lives of people with Primary Hyperoxaluria (PH), announces results of its pivotal Phase 3 study.

New OxThera/Oxabact US Patent Granted

UF startup OxThera AB, a privately-held biopharmaceutical company dedicated to improving the lives of people with Primary Hyperoxaluria (PH), announces that a new US patent has been granted for its product candidate Oxabact and a method for the treatment or prevention of an oxalate-related disorder, such as hyperoxaluria.

Plasma Oxalate and Kidney Function Are Correlated in Patients With Primary Hyperoxaluria With Maintained Kidney Function – Data From Three Placebo-Controlled Studies Published

UF startup OxThera AB, a privately-held biopharmaceutical company dedicated to improving the lives of people with Primary Hyperoxaluria (PH), announces the publication of an article in Pediatric Nephrology, on the significant correlation between plasma oxalate and kidney function in three controlled clinical trials with PH patients.
X